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reductase, ubiquinone cytochrome c reductase, and cytochrome c
oxidase) in EC compared to LDL or control. The abundance of
mitochondria-associated ROS and the release of ROS from EC were
significantly increased following glyLDL or oxLDL treatment. The
findings suggest that glyLDL attenuates activities of key enzymes in
multiple mitochondrial ETC, decreases mitochondrial oxygen con-
sumption and mitochondrial membrane potential, and increases ROS
generation from mitochondria in EC, which potentially contributes to
mitochondrial dysfunction and vascular disorders in diabetic patients.
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In humans, deficiency of complex I (CI or NADH:ubiquinone
oxidoreductase) is associated with a wide range of progressive
neurological disorders that are characterized by an early onset and a
short devastating course. CI resides in the mitochondrial inner
membrane (MIM), where it channels electrons from food-derived
NADH into the electron transport chain (ETC). Together with three
other complexes (CII-CIV) and the ATP-generating enzyme FOF1-
ATPase (CV), CI constitutes the mitochondrial oxidative phosphoryla-
tion system (OXPHOS). CI is a large (about 1 MDa) multi-subunit
complex that consists of 45 different subunits of which 7 are encoded
by the mitochondrial DNA (mtDNA) and the remainder by the
nuclear DNA (nDNA). To study the pathophysiology of CI dysfunction,
we use a novel knockout (KO) mouse model lacking an nDNA-
encoded CI subunit (NDUFS4), which is a mutational hotspot in
human CI deficiency. For this purpose we generated mouse
embryonic fibroblast (MEF) cell lines from wild type (WT) and KO
animals. Analysis of mitochondrial fractions revealed a greatly
reduced CI activity in KO MEFs (about 5% of WT), whereas other
activities (CII, CIII, CIV, CV and citrate synthase) were normal. At the
protein level, MEFs from KO animals lacked fully assembled CI but
instead contained a CI subcomplex of about 850 kDa. Reintroduction
of the NDUFS4 subunit in KO cells led to reappearance of the fully
assembled CI holocomplex. Functionally, KO MEFs contained mito-
chondria with a hyperpolarized membrane potential, probably due to
reverse-mode action of CV. When cultured in glucose-containing
(GLU) medium, reactive oxygen species (ROS) levels in WT and KO
cells were identical. However, when a galactose (GAL) medium was
used, KO MEFs displayed increased ROS levels whereas WT MEFs did
not. In KO MEFs, complementation of the NDUFS4 gene defect fully
normalized the increased ROS levels. NADP(H) levels in KO MEFs
were higher than in WT MEFs, whereas cytosolic resting [ATP]
(determined with the novel fluorescent ATP-sensor ‘ATeam’) where
the same. Currently, experiments are in progress to determine the
effects of NDUFS4 knockout on cytosolic calcium handling and
expression of energy-sensing proteins. Moreover, established anti-
oxidants and nutraceuticals are tested for their beneficial action on
WT and KO MEFs.
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Riboflavin-responsive multiple acyl-CoA dehydrogenase defi-
ciency (RR-MAD) is a lipid storage myopathy characterised by muscle
weakness, decreased β-oxidation and muscle carnitine, altered
urinary organic acids and plasma acyl-carnitine. We studied a cohort
of 11 RR-MAD patients, performing a battery of biochemical and
molecular tests to better characterise the metabolic disturbance of
this disease and to explore the pathophysiological events [1–3].
Biochemical alterations of pre-therapy patient muscles included:
(i) reduction in β-oxidation and in flavin-dependent enzymes (short
and medium-chain acyl coenzyme A dehydrogenases, complexes I
and II); (ii) reduction of FMN and FAD concentrations, (iii) increased
activity of mitochondrial FAD pyrophosphatase [1, 3], thus suggesting
an altered regulation of mitochondrial flavin cofactor homeostasis [4].
Proteomic investigation of muscle mitochondria in one RR-MAD
patient [3] revealed decrease or absence of several proteins. All these
deficiencies were completely rescued after riboflavin treatment.
Proteomic data indicate that the enzymatic defects are multiple,
coordinated, riboflavin-responsive and more extensive than pre-
viously described. In patients with RR-MAD the molecular defect is
still unknown. Recently it was described that RR-MAD is associated
with defects in electron transfer flavoprotein dehydrogenase (ETFDH)
gene in a large proportion of cases. Therefore we performed
molecular investigation by sequencing the ETFDH gene to identify
the defects in this group of RR-MAD patients. The genomic sequence
of each exon of ETFDH, including intron/exon boundaries has been
PCR-amplified for 30 cycles. The PCR products have been purified and
directly sequenced.
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